577 Results

People

  1. Morris
    Morris
  2. Scher
    Scher
  3. Slovin
    Slovin
  4. Larson
    Larson
  5. Heller
    Heller
  6. Rathkopf
    Rathkopf
  7. Danila
    Danila
  8. Pandit-Taskar
    Pandit-Taskar
  9. Abida
    Abida
  10. Autio
    Autio

Groups

  1. Department of Medicine (577)
  2. Genitourinary Oncology Service (577)
  3. Solid Tumor Oncology Division (577)
  4. Radiology, Department of (162)
  5. GSK Faculty (160)
  6. Molecular Imaging and Therapy Service (140)
  7. Sloan Kettering Institute Faculty (115)
  8. Epidemiology and Biostatistics (111)
  9. Molecular Pharmacology and Chemistry Program Faculty (110)
  10. Hematologic Malignancies, Division of (104)
  1. "Michael Morris"
Formats
  1. Meeting Abstract (273)
  2. Journal Article (263)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (577)
  2. Genitourinary Oncology Service (577)
  3. Solid Tumor Oncology Division (577)
  4. Radiology, Department of (162)
  5. GSK Faculty (160)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Michael Morris (577)
  2. Howard Scher (217)
  3. Steven Larson (93)
  4. Susan Slovin (90)
  5. Dana Rathkopf (79)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (18)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (246)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (577)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab
    Journal Article

    Nixon, A. B.; Liu, Y. M.; Yang, Q.; Luo, B.; Starr, M. D.; Brady, J. C.; Kelly, W. K.; Beltran, H.; Morris, M. J.; George, D. J.; more...
    Prostate Cancer and Prostatic Diseases (2025)

    Fulltext@MSK | Save
  • Defining the role of pragmatic clinical trials in cancer clinical research: Outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
    Journal Article

    Cardoso Borges, F.; van der Graaf, W. T. A.; Saesen, R.; Aebi, S.; Amariutei, A. E.; Bekelman, J.; Gorlia, T.; Hulstaert, F.; Huys, I.; Kluetz, P.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Kiess, A. P.; Nordquist, L.; Gupta, S.; George, D. J.; Messmann, R. A.; Kantoff, P. W.; Nauseef, J. T.; Bander, N. H.; Antonarakis, E. S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs)
    Meeting Abstract

    Roy, S.; Sun, Y. L.; Eastham, J. A.; Gleave, M.; Beltran, H.; Kishan, A. U.; Jia, A. Y.; Zaorsky, N. G.; Garcia, J. A.; Small, E. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy of (177)Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis
    Meeting Abstract

    Yazdanpanah, O.; Calais, J.; Chi, K. N.; De Bono, J. S.; Deymann, S.; El-Haddad, G.; Herrmann, K.; Fizazi, K.; Gonzalez, D. O.; Kendi, A. T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of (177)Lu-PSMA-617
    Meeting Abstract

    De Bono, J. S.; Morris, M. J.; Sartor, A. O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial
    Meeting Abstract

    Ryan, C. J.; Kim, H.; Morris, M. J.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Sharifi, N.; Halabi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance)
    Meeting Abstract

    Sharifi, N.; Kim, H.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Morris, M. J.; Halabi, S.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save